Document is current
Any future updates will be listed below
-
Authors
Puumala, Emily https://orcid.org/0009-0008-3371-5877
Nandakumar, Meganathan
Yiu, Bonnie
Stogios, Peter J. https://orcid.org/0000-0001-8663-1425
Strickland, Benjamin G.
Zarnowski, Robert https://orcid.org/0000-0001-6343-1500
Wang, Xiaoyu
Williams, Noelle S.
Savchenko, Alexei https://orcid.org/0000-0002-5256-9237
Andes, David R. https://orcid.org/0000-0002-7927-9950
Robbins, Nicole
Whitesell, Luke
Willson, Timothy M. https://orcid.org/0000-0003-4181-8223
Cowen, Leah E. https://orcid.org/0000-0001-5797-0110
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (1R01AI62789)
- License Information
-
More Information
Article History
Received: 3 December 2024
Accepted: 19 February 2025
First Online: 4 March 2025
Competing interests
: L.E.C. and L.W. are co-founders and shareholders in Bright Angel Therapeutics, a platform company for the development of novel antifungal therapeutics. L.E.C. is a Science Advisor for Kapoose Creek, a company that harnesses the therapeutic potential of fungi. All other authors declare no competing interests.
